Finafloxacin Brand Name– XTORO
What is Finafloxacin
Finafloxacin is a fluoroquinolone otic suspension approved for treatment of acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus.
Approval was based on the results of two clinical trials.
Data from these trials found recipients of finafloxacin achieved a 71% clinical cure rate at treatment day 11; of those clinically cured pathogen positive patients, the eradication rate for both P. aeruginosa and S. aureus was 89%.
Finafloxacin was FDA-approved for use in patients aged 1 year and older in December 2014.
Indications
- otitis externa
- Pseudomonas aeruginosa
- Staphylococcus aureus (MRSA)
- Staphylococcus aureus (MSSA)
Side Effects
- nausea
- pruritus
The most common adverse reactions reported in clinical trials with finafloxacin otic suspension were ear pruritus and nausea, which occurred at an incidence of 1%
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- antimicrobial resistance
- breast-feeding
- pregnancy
- quinolone hypersensitivity
- viral infection
Interactions
No information is available regarding drug interactions associated with Finafloxacin